Larvol Delta - MaxCyte-and-Wugen-Sign-Strategic-Platform-License-to-Expedite-ScaleUp-of-Clinical-and-Commercial-Manufacturing-of-Wugens-Investigational-Allogeneic-OfftheShelf-Cell-Therapies-for-Cancers

WU CART 007 - Wugen

https://www.globenewswire.com/news-release/2024/01/30/2819968/0/en/MaxCyte-and-Wugen-Sign-Strategic-Platform-License-to-Expedite-Scale-Up-of-Clinical-and-Commercial-Manufacturing-of-Wugen-s-Investigational-Allogeneic-Off-the-Shelf-Cell-Therapies-f.html

Jan 30, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next